<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01853397</url>
  </required_header>
  <id_info>
    <org_study_id>13-137-LP-H</org_study_id>
    <nct_id>NCT01853397</nct_id>
  </id_info>
  <brief_title>Evaluation of the Treatment of Adipose Tissue With Liposonix System (Model 2) Using a New Treatment Method</brief_title>
  <official_title>An Evaluation of the Safety and Effectiveness of Treatment of Adipose Tissue With the Liposonix System (Model 2) Using a New Treatment Method</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Solta Medical</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Valeant Pharmaceuticals</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to evaluate the safety, efficacy, and tolerability of treatment
      with the Liposonix System (Model 2)using a single pass technique.
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>April 2013</start_date>
  <completion_date type="Actual">February 2014</completion_date>
  <primary_completion_date type="Actual">February 2014</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Single (Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Change in Waist Circumference 12 Weeks After Treatment as Compared to Baseline</measure>
    <time_frame>12 weeks</time_frame>
    <description>Change from baseline in waist circumference 12 weeks after treatment was assessed by blinded evaluators.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Change in Waist Circumference 4,8, and16 Weeks After Treatment as Compared to Baseline</measure>
    <time_frame>4 weeks, 8 weeks, 16 weeks</time_frame>
    <description>Change from baseline in waist circumference 4, 8, and 16 weeks after treatment was assessed by blinded evaluators.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Investigator Assessment of Improvement Using Global Aesthetic Improvement Scale (GAIS)</measure>
    <time_frame>4, 8, 12, and 16 weeks</time_frame>
    <description>GAIS evaluations were performed by Investigators at the 4, 8, 12, and 16 week visits. Investigators used direct visual assessment (live assessment) compared to photographs of subjects taken before treatment (baseline) to assess improvement in the treatment area.
Scoring was based upon a five point grading System: 5 - Much Improved, 4 - Improved, 3 - No Change, 2 - Worse, or 1 - Much Worse. The definition of an improvement of the GAIS score included either a GAIS score of 'Improved' or 'Much Improved'.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Subject Assessment of Improvement Using Global Aesthetic Improvement Scale (GAIS)</measure>
    <time_frame>4, 8, 12, and 16 weeks</time_frame>
    <description>Subjects self-assessed improvement in the treatment area and assigned a GAIS score at each visit. Scoring was based upon a five point grading System: 5 - Much Improved, 4 - Improved, 3 - No Change, 2 - Worse, or 1 - Much Worse. The definition of an improvement of the GAIS score included either a GAIS score of 'Improved' or 'Much Improved'.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Subject Satisfaction With Treatment</measure>
    <time_frame>4, 8, 12, and 16 weeks</time_frame>
    <description>Subjects rated their satisfaction with treatment results using a 5-point Likert Satisfaction Scale (5: very satisfied; 4: satisfied; 3: neither satisfied nor dissatisfied; 2: dissatisfied; 1: very dissatisfied). The subject satisfaction score was analyzed as the proportion of subjects showing improvement as defined as a score of 4 or greater ('satisfied' or 'very satisfied').</description>
  </secondary_outcome>
  <number_of_arms>4</number_of_arms>
  <enrollment type="Actual">72</enrollment>
  <condition>Subcutaneous Adipose Tissue</condition>
  <arm_group>
    <arm_group_label>Treatment at level 1</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Single treatment with Liposonix System (Model 2) using single pass technique at level 1 (180 J/cm2)</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Treatment at level 2</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Single treatment with Liposonix System (Model 2)using the single pass technique at treatment level 2 (140 J/cm2)</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Treatment at level 3</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Single treatment with Liposonix System (Model 2)using single pass technique at level 3 (120 J/cm2)</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Treatment with 3 passes at 60 J/cm2</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Single treatment with Liposonix System (Model 2) using grid repeat technique with 3 passes at 60 J/cm2 (180 J/cm2 total fluence)</description>
  </arm_group>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>Liposonix System (Model 2)</intervention_name>
    <arm_group_label>Treatment at level 1</arm_group_label>
    <arm_group_label>Treatment at level 2</arm_group_label>
    <arm_group_label>Treatment at level 3</arm_group_label>
    <arm_group_label>Treatment with 3 passes at 60 J/cm2</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Male or female, 18 to 65 years of age

          -  Body Mass Index of ≤30 kg/m2

          -  Thickness of subcutaneous adipose tissue in the anticipated treatment area of ≥ 2.3 cm

          -  Subjects must agree to not alter their normal and regular diet or exercise routines
             during the course of the study

          -  Subject must understand the nature of the study and sign an IRB approved Informed
             Consent

        Exclusion Criteria:

          -  Subject is pregnant

          -  Subject is diagnosed with coagulation disorders or are receiving anticoagulant therapy
             or medications or dietary supplements which impede coagulation or platelet aggregation

          -  Subject has diabetes or cardiovascular disease

          -  Subject has had prior aesthetic procedures to the region to be treated

          -  Subject has had previous open or laparoscopic surgery in the anticipated treatment
             area

          -  Subject is on prescription or over the counter weight reduction medication or
             programs, or had weight reduction procedures

          -  Subjects undergoing chronic steroid or immunosuppressive therapy

          -  Subject has cardiac pacemakers or any implantable electrical device

          -  Subject has a History of cancer

          -  Subject has sensory loss or dysesthesia in the area to be treated

          -  Subjects who are unable, or lack the capacity, to self consent
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>65 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Mark Jewell, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Jewell Plastic Surgery Center</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Ronald Wheeland, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Solta Medical Aesthetic Center</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Solta Medical Aesthetic Center</name>
      <address>
        <city>Hayward</city>
        <state>California</state>
        <zip>94545</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Jewell Plastic Surgery Center</name>
      <address>
        <city>Eugene</city>
        <state>Oregon</state>
        <zip>97401</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>March 2015</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>May 8, 2013</study_first_submitted>
  <study_first_submitted_qc>May 10, 2013</study_first_submitted_qc>
  <study_first_posted type="Estimate">May 15, 2013</study_first_posted>
  <results_first_submitted>March 17, 2015</results_first_submitted>
  <results_first_submitted_qc>March 17, 2015</results_first_submitted_qc>
  <results_first_posted type="Estimate">March 27, 2015</results_first_posted>
  <last_update_submitted>March 26, 2015</last_update_submitted>
  <last_update_submitted_qc>March 26, 2015</last_update_submitted_qc>
  <last_update_posted type="Estimate">April 16, 2015</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>

  <clinical_results>

    <participant_flow>
      <group_list>
        <group group_id="P1">
          <title>Treatment at Level 1</title>
          <description>Single treatment with Liposonix System (Model 2) using single pass technique at level 1 (180 J/cm2)
Liposonix System (Model 2)</description>
        </group>
        <group group_id="P2">
          <title>Treatment at Level 2</title>
          <description>Single treatment with Liposonix System (Model 2)using the single pass technique at treatment level 2 (140 J/cm2)
Liposonix System (Model 2)</description>
        </group>
        <group group_id="P3">
          <title>Treatment at Level 3</title>
          <description>Single treatment with Liposonix System (Model 2)using single pass technique at level 3 (120 J/cm2)
Liposonix System (Model 2)</description>
        </group>
        <group group_id="P4">
          <title>Treatment With 3 Passes at 60 J/cm2</title>
          <description>Single treatment with Liposonix System (Model 2) using grid repeat technique with 3 passes at 60 J/cm2 (180 J/cm2 total fluence)
Liposonix System (Model 2)</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="18"/>
                <participants group_id="P2" count="20"/>
                <participants group_id="P3" count="17"/>
                <participants group_id="P4" count="17"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="18"/>
                <participants group_id="P2" count="20"/>
                <participants group_id="P3" count="17"/>
                <participants group_id="P4" count="15"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="0"/>
                <participants group_id="P4" count="2"/>
              </participants_list>
            </milestone>
          </milestone_list>
          <drop_withdraw_reason_list>
            <drop_withdraw_reason>
              <title>Withdrawal by Subject</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="0"/>
                <participants group_id="P4" count="1"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Subject Noncompliance</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="0"/>
                <participants group_id="P4" count="1"/>
              </participants_list>
            </drop_withdraw_reason>
          </drop_withdraw_reason_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <group_list>
        <group group_id="B1">
          <title>Treatment at Level 1</title>
          <description>Single treatment with Liposonix System (Model 2) using single pass technique at level 1 (180 J/cm2)
Liposonix System (Model 2)</description>
        </group>
        <group group_id="B2">
          <title>Treatment at Level 2</title>
          <description>Single treatment with Liposonix System (Model 2)using the single pass technique at treatment level 2 (140 J/cm2)
Liposonix System (Model 2)</description>
        </group>
        <group group_id="B3">
          <title>Treatment at Level 3</title>
          <description>Single treatment with Liposonix System (Model 2)using single pass technique at level 3 (120 J/cm2)
Liposonix System (Model 2)</description>
        </group>
        <group group_id="B4">
          <title>Treatment With 3 Passes at 60 J/cm2</title>
          <description>Single treatment with Liposonix System (Model 2) using grid repeat technique with 3 passes at 60 J/cm2 (180 J/cm2 total fluence)
Liposonix System (Model 2)</description>
        </group>
        <group group_id="B5">
          <title>Total</title>
          <description>Total of all reporting groups</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="18"/>
            <count group_id="B2" value="20"/>
            <count group_id="B3" value="17"/>
            <count group_id="B4" value="17"/>
            <count group_id="B5" value="72"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>years</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="44.4" spread="10.2"/>
                    <measurement group_id="B2" value="45.9" spread="12.3"/>
                    <measurement group_id="B3" value="42.4" spread="7.8"/>
                    <measurement group_id="B4" value="38.8" spread="10.9"/>
                    <measurement group_id="B5" value="43.0" spread="10.4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Gender</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>Female</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="17"/>
                    <measurement group_id="B2" value="15"/>
                    <measurement group_id="B3" value="16"/>
                    <measurement group_id="B4" value="16"/>
                    <measurement group_id="B5" value="64"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Male</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="1"/>
                    <measurement group_id="B2" value="5"/>
                    <measurement group_id="B3" value="1"/>
                    <measurement group_id="B4" value="1"/>
                    <measurement group_id="B5" value="8"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Region of Enrollment</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>United States</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="18"/>
                    <measurement group_id="B2" value="20"/>
                    <measurement group_id="B3" value="17"/>
                    <measurement group_id="B4" value="17"/>
                    <measurement group_id="B5" value="72"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Body Mass Index</title>
          <units>kg/m^2</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="25.9" spread="2.4"/>
                    <measurement group_id="B2" value="25.2" spread="2.8"/>
                    <measurement group_id="B3" value="25.5" spread="2.8"/>
                    <measurement group_id="B4" value="25.4" spread="2.1"/>
                    <measurement group_id="B5" value="25.5" spread="2.5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Change in Waist Circumference 12 Weeks After Treatment as Compared to Baseline</title>
        <description>Change from baseline in waist circumference 12 weeks after treatment was assessed by blinded evaluators.</description>
        <time_frame>12 weeks</time_frame>
        <population>Intent-to-treat</population>
        <group_list>
          <group group_id="O1">
            <title>Treatment at Level 1</title>
            <description>Single treatment with Liposonix System (Model 2) using single pass technique at level 1 (180 J/cm2)
Liposonix System (Model 2)</description>
          </group>
          <group group_id="O2">
            <title>Treatment at Level 2</title>
            <description>Single treatment with Liposonix System (Model 2)using the single pass technique at treatment level 2 (140 J/cm2)
Liposonix System (Model 2)</description>
          </group>
          <group group_id="O3">
            <title>Treatment at Level 3</title>
            <description>Single treatment with Liposonix System (Model 2)using single pass technique at level 3 (120 J/cm2)
Liposonix System (Model 2)</description>
          </group>
          <group group_id="O4">
            <title>Treatment With 3 Passes at 60 J/cm2</title>
            <description>Single treatment with Liposonix System (Model 2) using grid repeat technique with 3 passes at 60 J/cm2 (180 J/cm2 total fluence)
Liposonix System (Model 2)</description>
          </group>
        </group_list>
        <measure>
          <title>Change in Waist Circumference 12 Weeks After Treatment as Compared to Baseline</title>
          <description>Change from baseline in waist circumference 12 weeks after treatment was assessed by blinded evaluators.</description>
          <population>Intent-to-treat</population>
          <units>cm</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="18"/>
                <count group_id="O2" value="20"/>
                <count group_id="O3" value="17"/>
                <count group_id="O4" value="17"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-1.6" spread="1.6"/>
                    <measurement group_id="O2" value="-.96" spread="2.6"/>
                    <measurement group_id="O3" value="-1.4" spread="2.4"/>
                    <measurement group_id="O4" value="-1.2" spread="1.5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change in Waist Circumference 4,8, and16 Weeks After Treatment as Compared to Baseline</title>
        <description>Change from baseline in waist circumference 4, 8, and 16 weeks after treatment was assessed by blinded evaluators.</description>
        <time_frame>4 weeks, 8 weeks, 16 weeks</time_frame>
        <population>Intent-to-treat</population>
        <group_list>
          <group group_id="O1">
            <title>Treatment at Level 1</title>
            <description>Single treatment with Liposonix System (Model 2) using single pass technique at level 1 (180 J/cm2)
Liposonix System (Model 2)</description>
          </group>
          <group group_id="O2">
            <title>Treatment at Level 2</title>
            <description>Single treatment with Liposonix System (Model 2)using the single pass technique at treatment level 2 (140 J/cm2)
Liposonix System (Model 2)</description>
          </group>
          <group group_id="O3">
            <title>Treatment at Level 3</title>
            <description>Single treatment with Liposonix System (Model 2)using single pass technique at level 3 (120 J/cm2)
Liposonix System (Model 2)</description>
          </group>
          <group group_id="O4">
            <title>Treatment With 3 Passes at 60 J/cm2</title>
            <description>Single treatment with Liposonix System (Model 2) using grid repeat technique with 3 passes at 60 J/cm2 (180 J/cm2 total fluence)
Liposonix System (Model 2)</description>
          </group>
        </group_list>
        <measure>
          <title>Change in Waist Circumference 4,8, and16 Weeks After Treatment as Compared to Baseline</title>
          <description>Change from baseline in waist circumference 4, 8, and 16 weeks after treatment was assessed by blinded evaluators.</description>
          <population>Intent-to-treat</population>
          <units>cm</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="18"/>
                <count group_id="O2" value="20"/>
                <count group_id="O3" value="17"/>
                <count group_id="O4" value="17"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>4 weeks</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-0.66" spread="1.0"/>
                    <measurement group_id="O2" value="-0.73" spread="1.6"/>
                    <measurement group_id="O3" value="-0.86" spread="1.2"/>
                    <measurement group_id="O4" value="-0.44" spread="0.9"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>8 weeks</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-0.76" spread="1.3"/>
                    <measurement group_id="O2" value="-1.3" spread="2.2"/>
                    <measurement group_id="O3" value="-1.5" spread="1.7"/>
                    <measurement group_id="O4" value="-0.92" spread="1.6"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>16 weeks</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-1.8" spread="2.0"/>
                    <measurement group_id="O2" value="-1.2" spread="3.0"/>
                    <measurement group_id="O3" value="-1.4" spread="1.6"/>
                    <measurement group_id="O4" value="-0.99" spread="2.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Investigator Assessment of Improvement Using Global Aesthetic Improvement Scale (GAIS)</title>
        <description>GAIS evaluations were performed by Investigators at the 4, 8, 12, and 16 week visits. Investigators used direct visual assessment (live assessment) compared to photographs of subjects taken before treatment (baseline) to assess improvement in the treatment area.
Scoring was based upon a five point grading System: 5 - Much Improved, 4 - Improved, 3 - No Change, 2 - Worse, or 1 - Much Worse. The definition of an improvement of the GAIS score included either a GAIS score of ‘Improved’ or ‘Much Improved’.</description>
        <time_frame>4, 8, 12, and 16 weeks</time_frame>
        <population>Intent-to-treat</population>
        <group_list>
          <group group_id="O1">
            <title>Treatment at Level 1</title>
            <description>Single treatment with Liposonix System (Model 2) using single pass technique at level 1 (180 J/cm2)
Liposonix System (Model 2)</description>
          </group>
          <group group_id="O2">
            <title>Treatment at Level 2</title>
            <description>Single treatment with Liposonix System (Model 2)using the single pass technique at treatment level 2 (140 J/cm2)
Liposonix System (Model 2)</description>
          </group>
          <group group_id="O3">
            <title>Treatment at Level 3</title>
            <description>Single treatment with Liposonix System (Model 2)using single pass technique at level 3 (120 J/cm2)
Liposonix System (Model 2)</description>
          </group>
          <group group_id="O4">
            <title>Treatment With 3 Passes at 60 J/cm2</title>
            <description>Single treatment with Liposonix System (Model 2) using grid repeat technique with 3 passes at 60 J/cm2 (180 J/cm2 total fluence)
Liposonix System (Model 2)</description>
          </group>
        </group_list>
        <measure>
          <title>Investigator Assessment of Improvement Using Global Aesthetic Improvement Scale (GAIS)</title>
          <description>GAIS evaluations were performed by Investigators at the 4, 8, 12, and 16 week visits. Investigators used direct visual assessment (live assessment) compared to photographs of subjects taken before treatment (baseline) to assess improvement in the treatment area.
Scoring was based upon a five point grading System: 5 - Much Improved, 4 - Improved, 3 - No Change, 2 - Worse, or 1 - Much Worse. The definition of an improvement of the GAIS score included either a GAIS score of ‘Improved’ or ‘Much Improved’.</description>
          <population>Intent-to-treat</population>
          <units>Percentage of subjects improved</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="18"/>
                <count group_id="O2" value="20"/>
                <count group_id="O3" value="17"/>
                <count group_id="O4" value="17"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>4 weeks</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="66.6"/>
                    <measurement group_id="O2" value="55.0"/>
                    <measurement group_id="O3" value="47.0"/>
                    <measurement group_id="O4" value="47.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>8 weeks</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="72.2"/>
                    <measurement group_id="O2" value="75.0"/>
                    <measurement group_id="O3" value="76.4"/>
                    <measurement group_id="O4" value="76.4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>12 weeks</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="83.3"/>
                    <measurement group_id="O2" value="80.0"/>
                    <measurement group_id="O3" value="76.4"/>
                    <measurement group_id="O4" value="68.8"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>16 weeks</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="83.3"/>
                    <measurement group_id="O2" value="75.0"/>
                    <measurement group_id="O3" value="64.7"/>
                    <measurement group_id="O4" value="73.3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Subject Assessment of Improvement Using Global Aesthetic Improvement Scale (GAIS)</title>
        <description>Subjects self-assessed improvement in the treatment area and assigned a GAIS score at each visit. Scoring was based upon a five point grading System: 5 - Much Improved, 4 - Improved, 3 - No Change, 2 - Worse, or 1 - Much Worse. The definition of an improvement of the GAIS score included either a GAIS score of ‘Improved’ or ‘Much Improved’.</description>
        <time_frame>4, 8, 12, and 16 weeks</time_frame>
        <population>Intent-to-treat</population>
        <group_list>
          <group group_id="O1">
            <title>Treatment at Level 1</title>
            <description>Single treatment with Liposonix System (Model 2) using single pass technique at level 1 (180 J/cm2)
Liposonix System (Model 2)</description>
          </group>
          <group group_id="O2">
            <title>Treatment at Level 2</title>
            <description>Single treatment with Liposonix System (Model 2)using the single pass technique at treatment level 2 (140 J/cm2)
Liposonix System (Model 2)</description>
          </group>
          <group group_id="O3">
            <title>Treatment at Level 3</title>
            <description>Single treatment with Liposonix System (Model 2)using single pass technique at level 3 (120 J/cm2)
Liposonix System (Model 2)</description>
          </group>
          <group group_id="O4">
            <title>Treatment With 3 Passes at 60 J/cm2</title>
            <description>Single treatment with Liposonix System (Model 2) using grid repeat technique with 3 passes at 60 J/cm2 (180 J/cm2 total fluence)
Liposonix System (Model 2)</description>
          </group>
        </group_list>
        <measure>
          <title>Subject Assessment of Improvement Using Global Aesthetic Improvement Scale (GAIS)</title>
          <description>Subjects self-assessed improvement in the treatment area and assigned a GAIS score at each visit. Scoring was based upon a five point grading System: 5 - Much Improved, 4 - Improved, 3 - No Change, 2 - Worse, or 1 - Much Worse. The definition of an improvement of the GAIS score included either a GAIS score of ‘Improved’ or ‘Much Improved’.</description>
          <population>Intent-to-treat</population>
          <units>percentage of subjects improved</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="18"/>
                <count group_id="O2" value="20"/>
                <count group_id="O3" value="17"/>
                <count group_id="O4" value="17"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>4 weeks</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="77.7"/>
                    <measurement group_id="O2" value="55.0"/>
                    <measurement group_id="O3" value="52.9"/>
                    <measurement group_id="O4" value="52.9"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>8 weeks</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="61.1"/>
                    <measurement group_id="O2" value="84.2"/>
                    <measurement group_id="O3" value="70.5"/>
                    <measurement group_id="O4" value="76.4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>12 weeks</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="72.2"/>
                    <measurement group_id="O2" value="100"/>
                    <measurement group_id="O3" value="68.8"/>
                    <measurement group_id="O4" value="75.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>16 weeks</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="77.7"/>
                    <measurement group_id="O2" value="75.0"/>
                    <measurement group_id="O3" value="64.7"/>
                    <measurement group_id="O4" value="73.3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Subject Satisfaction With Treatment</title>
        <description>Subjects rated their satisfaction with treatment results using a 5-point Likert Satisfaction Scale (5: very satisfied; 4: satisfied; 3: neither satisfied nor dissatisfied; 2: dissatisfied; 1: very dissatisfied). The subject satisfaction score was analyzed as the proportion of subjects showing improvement as defined as a score of 4 or greater (‘satisfied’ or ‘very satisfied’).</description>
        <time_frame>4, 8, 12, and 16 weeks</time_frame>
        <population>Intent-to-treat</population>
        <group_list>
          <group group_id="O1">
            <title>Treatment at Level 1</title>
            <description>Single treatment with Liposonix System (Model 2) using single pass technique at level 1 (180 J/cm2)
Liposonix System (Model 2)</description>
          </group>
          <group group_id="O2">
            <title>Treatment at Level 2</title>
            <description>Single treatment with Liposonix System (Model 2)using the single pass technique at treatment level 2 (140 J/cm2)
Liposonix System (Model 2)</description>
          </group>
          <group group_id="O3">
            <title>Treatment at Level 3</title>
            <description>Single treatment with Liposonix System (Model 2)using single pass technique at level 3 (120 J/cm2)
Liposonix System (Model 2)</description>
          </group>
          <group group_id="O4">
            <title>Treatment With 3 Passes at 60 J/cm2</title>
            <description>Single treatment with Liposonix System (Model 2) using grid repeat technique with 3 passes at 60 J/cm2 (180 J/cm2 total fluence)
Liposonix System (Model 2)</description>
          </group>
        </group_list>
        <measure>
          <title>Subject Satisfaction With Treatment</title>
          <description>Subjects rated their satisfaction with treatment results using a 5-point Likert Satisfaction Scale (5: very satisfied; 4: satisfied; 3: neither satisfied nor dissatisfied; 2: dissatisfied; 1: very dissatisfied). The subject satisfaction score was analyzed as the proportion of subjects showing improvement as defined as a score of 4 or greater (‘satisfied’ or ‘very satisfied’).</description>
          <population>Intent-to-treat</population>
          <units>percentage of subjects satisfied</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="18"/>
                <count group_id="O2" value="20"/>
                <count group_id="O3" value="17"/>
                <count group_id="O4" value="17"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>4 weeks</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="61.1"/>
                    <measurement group_id="O2" value="55.0"/>
                    <measurement group_id="O3" value="41.1"/>
                    <measurement group_id="O4" value="58.8"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>8 weeks</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="61.1"/>
                    <measurement group_id="O2" value="78.9"/>
                    <measurement group_id="O3" value="52.9"/>
                    <measurement group_id="O4" value="52.9"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>12 weeks</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="64.7"/>
                    <measurement group_id="O2" value="73.6"/>
                    <measurement group_id="O3" value="62.5"/>
                    <measurement group_id="O4" value="68.8"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>16 weeks</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="61.1"/>
                    <measurement group_id="O2" value="75.0"/>
                    <measurement group_id="O3" value="64.7"/>
                    <measurement group_id="O4" value="60.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
    </outcome_list>

    <reported_events>
      <time_frame>Adverse events were collected from day 0 through study exit</time_frame>
      <group_list>
        <group group_id="E1">
          <title>Treatment at Level 1</title>
          <description>Single treatment with Liposonix System (Model 2) using single pass technique at level 1 (180 J/cm2)
Liposonix System (Model 2)</description>
        </group>
        <group group_id="E2">
          <title>Treatment at Level 2</title>
          <description>Single treatment with Liposonix System (Model 2)using the single pass technique at treatment level 2 (140 J/cm2)
Liposonix System (Model 2)</description>
        </group>
        <group group_id="E3">
          <title>Treatment at Level 3</title>
          <description>Single treatment with Liposonix System (Model 2)using single pass technique at level 3 (120 J/cm2)
Liposonix System (Model 2)</description>
        </group>
        <group group_id="E4">
          <title>Treatment With 3 Passes at 60 J/cm2</title>
          <description>Single treatment with Liposonix System (Model 2) using grid repeat technique with 3 passes at 60 J/cm2 (180 J/cm2 total fluence)
Liposonix System (Model 2)</description>
        </group>
      </group_list>
      <serious_events>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="18"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="20"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="17"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="17"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>0</frequency_threshold>
        <default_assessment>Non-systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="18" subjects_at_risk="18"/>
                <counts group_id="E2" subjects_affected="20" subjects_at_risk="20"/>
                <counts group_id="E3" subjects_affected="17" subjects_at_risk="17"/>
                <counts group_id="E4" subjects_affected="17" subjects_at_risk="17"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Gastrointestinal disorders</title>
            <event_list>
              <event>
                <sub_title>Constipation</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="18"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="20"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="17"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="17"/>
              </event>
              <event>
                <sub_title>Nausea/vomiting</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="18"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="20"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="17"/>
                <counts group_id="E4" events="3" subjects_affected="2" subjects_at_risk="17"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>General disorders</title>
            <event_list>
              <event>
                <sub_title>Abdominal discomfort</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="18"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="20"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="17"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="17"/>
              </event>
              <event>
                <sub_title>Burning sensation</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="18"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="20"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="17"/>
                <counts group_id="E4" events="2" subjects_affected="2" subjects_at_risk="17"/>
              </event>
              <event>
                <sub_title>Ecchymosis</sub_title>
                <counts group_id="E1" events="16" subjects_affected="16" subjects_at_risk="18"/>
                <counts group_id="E2" events="20" subjects_affected="20" subjects_at_risk="20"/>
                <counts group_id="E3" events="18" subjects_affected="17" subjects_at_risk="17"/>
                <counts group_id="E4" events="16" subjects_affected="16" subjects_at_risk="17"/>
              </event>
              <event>
                <sub_title>Fatigue</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="18"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="20"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="17"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="17"/>
              </event>
              <event>
                <sub_title>Pyrexia</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="18"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="20"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="17"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="17"/>
              </event>
              <event>
                <sub_title>Pain during treatment</sub_title>
                <counts group_id="E1" events="13" subjects_affected="13" subjects_at_risk="18"/>
                <counts group_id="E2" events="13" subjects_affected="13" subjects_at_risk="20"/>
                <counts group_id="E3" events="11" subjects_affected="11" subjects_at_risk="17"/>
                <counts group_id="E4" events="10" subjects_affected="10" subjects_at_risk="17"/>
              </event>
              <event>
                <sub_title>Pain/tenderness</sub_title>
                <counts group_id="E1" events="20" subjects_affected="17" subjects_at_risk="18"/>
                <counts group_id="E2" events="19" subjects_affected="16" subjects_at_risk="20"/>
                <counts group_id="E3" events="20" subjects_affected="16" subjects_at_risk="17"/>
                <counts group_id="E4" events="20" subjects_affected="16" subjects_at_risk="17"/>
              </event>
              <event>
                <sub_title>Paresthesia</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="18"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="20"/>
                <counts group_id="E3" events="3" subjects_affected="3" subjects_at_risk="17"/>
                <counts group_id="E4" events="2" subjects_affected="2" subjects_at_risk="17"/>
              </event>
              <event>
                <sub_title>Lumps/bumps</sub_title>
                <counts group_id="E1" events="3" subjects_affected="3" subjects_at_risk="18"/>
                <counts group_id="E2" events="6" subjects_affected="6" subjects_at_risk="20"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="17"/>
                <counts group_id="E4" events="2" subjects_affected="2" subjects_at_risk="17"/>
              </event>
              <event>
                <sub_title>Soreness/discomfort</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="18"/>
                <counts group_id="E2" events="4" subjects_affected="4" subjects_at_risk="20"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="17"/>
                <counts group_id="E4" events="3" subjects_affected="3" subjects_at_risk="17"/>
              </event>
              <event>
                <sub_title>Swelling</sub_title>
                <counts group_id="E1" events="7" subjects_affected="7" subjects_at_risk="18"/>
                <counts group_id="E2" events="8" subjects_affected="8" subjects_at_risk="20"/>
                <counts group_id="E3" events="7" subjects_affected="7" subjects_at_risk="17"/>
                <counts group_id="E4" events="7" subjects_affected="7" subjects_at_risk="17"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Infections and infestations</title>
            <event_list>
              <event>
                <sub_title>Bronchitis</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="18"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="20"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="17"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="17"/>
              </event>
              <event>
                <sub_title>Upper resp. tract infection</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="18"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="20"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="17"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="17"/>
              </event>
              <event>
                <sub_title>Infected arthropod bite</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="18"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="20"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="17"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="17"/>
              </event>
              <event>
                <sub_title>Sinusitis</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="18"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="20"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="17"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="17"/>
              </event>
              <event>
                <sub_title>Pharyngitis streptococcal</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="18"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="20"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="17"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="17"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Injury, poisoning and procedural complications</title>
            <event_list>
              <event>
                <sub_title>Tooth fracture</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="18"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="20"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="17"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="17"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Musculoskeletal and connective tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Bone fracture</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="18"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="20"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="17"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="17"/>
              </event>
              <event>
                <sub_title>Intervertebral disc protrusion</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="18"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="20"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="17"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="17"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Nervous system disorders</title>
            <event_list>
              <event>
                <sub_title>Headache</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="18"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="20"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="17"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="17"/>
              </event>
              <event>
                <sub_title>Vasovagal episode</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="18"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="20"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="17"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="17"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Psychiatric disorders</title>
            <event_list>
              <event>
                <sub_title>Depression</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="18"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="20"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="17"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="17"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Renal and urinary disorders</title>
            <event_list>
              <event>
                <sub_title>Chromaturia</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="18"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="20"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="17"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="17"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Skin and subcutaneous tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Acne</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="18"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="20"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="17"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="17"/>
              </event>
              <event>
                <sub_title>Angioedema</sub_title>
                <counts group_id="E1" events="5" subjects_affected="5" subjects_at_risk="18"/>
                <counts group_id="E2" events="5" subjects_affected="5" subjects_at_risk="20"/>
                <counts group_id="E3" events="5" subjects_affected="5" subjects_at_risk="17"/>
                <counts group_id="E4" events="5" subjects_affected="5" subjects_at_risk="17"/>
              </event>
              <event>
                <sub_title>Erythema</sub_title>
                <counts group_id="E1" events="16" subjects_affected="16" subjects_at_risk="18"/>
                <counts group_id="E2" events="14" subjects_affected="14" subjects_at_risk="20"/>
                <counts group_id="E3" events="13" subjects_affected="13" subjects_at_risk="17"/>
                <counts group_id="E4" events="12" subjects_affected="12" subjects_at_risk="17"/>
              </event>
              <event>
                <sub_title>Pruritus</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="18"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="20"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="17"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="17"/>
              </event>
              <event>
                <sub_title>Urticaria</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="18"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="20"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="17"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="17"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>Principal Investigators are NOT employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>Authorship and manuscript composition will reflect joint cooperation between the PI and Solta Medical personnel. Authorship will be established prior to the writing of the manuscript. No individual publications will be allowed prior to completion of the final report of the study except as agreed with Solta Medical. All publications must be reviewed and approved by Solta Medical prior to submission for publication.</restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>Director of Clinical Programs</name_or_title>
      <organization>Solta Medical</organization>
      <phone>510-259-5284</phone>
      <email>aloncaric@solta.com</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

